Government ❯Regulatory Agencies ❯FDA

Drug Approval Process

Compounding Regulations MDMA for PTSD MDMA Trials Alzheimer's Drug Approval Insulin Icodec MDMA Approval Psychedelic Drugs Clinical Trials Clinical Trial Regulations Ranitidine Regulations Public Health Regulations Public Health Medication Safety Over-the-Counter Medications Accelerated Approval Tirzepatide Supply Breakthrough Therapy Designation Mifepristone Legislation Compliance MDMA

FDA Declares Semaglutide Shortage Over, Impacting Compounded Drug Market

FDA to Decide on First Twice-Yearly HIV Prevention Shot by June

Eli Lilly Lowers 2024 Revenue Forecast Due to Slower Weight-Loss Drug Growth

FDA Moves to Ban Ineffective Cold Medicine Ingredient

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

Eli Lilly Sues Vendors for Selling Unauthorized Tirzepatide Products

CEO Sentenced to 3 Years for Selling Unapproved Stem Cell Treatments

FDA Declines MDMA for PTSD Treatment, Requests Further Trials

FDA Rejects MDMA for PTSD Treatment, Requests More Trials

FDA Panel Rejects MDMA for PTSD Treatment Over Data Concerns